GENERAL COMMENTS
The economic methods, data sources, and description of the analysis are acceptable. The major flaws with this study are:
1) the economic evaluation is based on a fundamentally flawed intervention trial. The original study appeared to be significantly underpowered for a brief clinical intervention. Most studies would need at least 630 ppts in each group in order to have a chance of detecting an intervention effect, assuming 80% power/.05 alpha to detect a 5% abstinence rate difference between the intervention and control groups. The power calculation on page 9 of the supplement suggested that the brief intervention recipients would be twice as likely (RR of 2.0) to be abstinent at 6-months compared to usual care, assuming a 10% abstinence rate in the UC group. These are not realistic assumptions. A brief clinic intervention will not double abstinent rates, especially since 73% of UC patients received some in-office provider counseling. The 8% abstinent rate in both groups is about what one would expect in patients receiving brief counseling in an outpatient clinic setting.
The lack of an intervention effect from a trial is typically considered a fatal flaw for a cost-effectiveness analysis. The authors attempt to rescue this evaluation by broadening the scope into a larger "what if" evaluation. The remaining flaws below are based on an assumption that there is value to conducting the "what if" modeling of a dental clinic smoking cessation intervention.
2) the economic analysis uses only about half of the original population of the original trial (n=205). The underpowered main trial raises an additional question of whether the original study was appropriately powered to detect differences in economic outcomes.
Reducing the sample by about half adds to this concern. The authors imply that the sample was reduced because smokers under age 20 were excluded, but the reader is left unsure. Participant cost data are messy in clinical trials, so it would have been good to know if the sample was reduced solely because of the age restriction or if other factors were involved (other than the small percent lost to follow-up).
3) the authors assumed that the observed differential reduction in amount smoked at 6 months (the only difference between I and UC groups) would lead to substantial quitting additional quitting among the intervention group compared to the UC group. The support for this assumption relies on studies conducted in the 1980s and 1990s, when smoking rates and cigarettes per day were higher that today.
The Hyland et al. (2005) study is actually a re-evaluation of an earlier study (Hughes et al., 1999) using longer follow-up of COMMIT study participants (enrolled between 1988 and 1993) . The Hughes analysis found that after 2 and 4 years of follow-up, reducing quantity smoked did not increase quitting. However, Hyland examined follow-up through 2001 and found that those who reduced smoking amount by >50% had a 1.7 higher likelihood of quitting compared to other participants. The implication for this study is that it appears to have taken 10 years to produce an intervention effect associated with reducing the quantity smoked. This would substantially extend the timing of any intervention effect associated with reduced smoking. This does not appear to have been considered. 4) A "do nothing" approach assumed no smokers quit, which is not realistic. Annual population-level quitting in adult populations is between 3-5%. It does not appear that the model allowed for independent quitting, which biases the results toward
5) The analysis suggests that the intervention produced worse quit outcomes than usual care. This is absurd, and is likely the result of random variation among low numbers of study participants in each age group. This is a fundamental flaw associated with the small study sample size.
The economic analysis (limited to mean intervention cost and cost/quit) should have been added to the primary outcome paper. There is not enough information from the study to support a separate economic evaluation that was presented in this paper. The cost effectiveness of dental clinic smoking cessation is an important issue. However, using this intervention trial as a vehicle is not convincing.
REVIEWER

Mary Lou Chatterton
Deakin University Australia REVIEW RETURNED 13-Mar-2017
GENERAL COMMENTS
Typically when an intervention is found not to be effective a costeffectiveness evaluation isn"t undertaken. The primary trial did not meet its primary endpoint of 7 day abstinence, but did achieve a significant difference in a secondary outcome measure (reduction in tobacco consumption) which would warrant an analysis of the estimated cost-effectiveness. So this evaluation has utility to health care policy makers. However, there are a few areas of the manuscript that would benefit from revision as noted below:
The introductory paragraph discusses cigarette smoking while the remaining sections discussion tobacco cessation. Given that the intervention is not exclusive to cigarettes but includes oral tobacco (snus) it may be useful to discuss the burden of all tobacco use if that is available. It may also be helpful to readers to define snus. I found the reference to Bolin [15] in the introduction confusing. Bolin provides a comprehensive documentation of the models used in economic evaluations of smoking cessation treatments and provides conclusions around improvements to the methods and reporting for these models. It does not recommend a particular type of model for a particular purpose. A Markov model evaluates cohorts which can be representative of a population. Therefore the distinction the authors make between population-based models and Markov models is unclear.
There were a few questions regarding the use of the trial results in this economic evaluation: 1)Why did the economic analysis only use data from those aged 20 or older? And 2)Why weren"t the main trial results specifically provided? It would assist the reader if there was a more compelling reason to explain why this economic evaluation with two different models is useful to clinicians and decision makers. It may not be appropriate to spread the intervention costs over 5 years (20% each year) as it is currently described. If the actual training occurs in year 1 then these costs should be allocated there.
Otherwise the costs being spread out over 5 years may decrease the intervention costs since they would be discounted at 3% in years 2-5. For clarity it would be useful if the authors defined which costs were included in each perspective since both health sector and societal perspectives are presented.
The rationale for the choice of 2014 as the reference year for costs should be noted. From my brief review of the report describing the Risk factors, Health and Societal Costs model, it appears that the original model evaluates the risk of specific cancer diagnoses associated with risk factors such as daily smoking, obesity etc. and that the authors adaptation was to include diabetes mellitus type 2 etc. It would be useful to note what outcomes were originally included in the model and which were added/adapted for this current evaluation. Additional detail regarding the main study endpoints and how they are adapted for use in the models would be helpful to the reader. In the current manuscript a description of how the QALYs are calculated should be added. It would help the reader if there was additional information in table 3 such as the fact the data provided was compared to the do nothing alternative. At the moment it is not clear without reading the text. It would be useful if the results for both models were stated using economic evaluation terminology such as "incremental cost effectiveness" and "dominant" interventions. The brief novel counselling was dominated by the usual care option (meaning it was the least costly alternative and was also estimated to deliver more QALYs). I don"t entirely agree with the discussion that, " The opposite conclusions from the two models are probably best explained by the difference in the population to which the simulation is applied." The fact that the Markov model included medications and lost productivity costs as well as covered a lifetime horizon are additional reasons for differences in the results.
REVIEWER
Tim Newton
King's College London, Unted Kingdom REVIEW RETURNED 14-Mar-2017
GENERAL COMMENTS
This is a well designed health economics analysis of the costeffectiveness of a brief tobacco cessation intervention in dental settings. Two different methods for estimation are compared with valuable results demonstrating the impact on population versus individual well being.
I have previously reviewed this manuscript and my only comment at that time was to ask the authors to insert some discussion in the Introduction as to why we would a priori need to evaluate brief interventions in dental settings given our knowledge of the effectiveness of brief interventions in other settings. THis has been done and therefore I am happy to recommend acceptance subject to review by a health economist. 
VERSION 1 -AUTHOR RESPONSE
Please leave your comments for the authors below The economic methods, data sources, and description of the analysis are acceptable. The major flaws with this study are:
1) the economic evaluation is based on a fundamentally flawed intervention trial. The original study appeared to be significantly underpowered for a brief clinical intervention. Most studies would need at least 630 ppts in each group in order to have a chance of detecting an intervention effect, assuming 80% power/.05 alpha to detect a 5% abstinence rate difference between the intervention and control groups. The power calculation on page 9 of the supplement suggested that the brief intervention recipients would be twice as likely (RR of 2.0) to be abstinent at 6-months compared to usual care, assuming a 10% abstinence rate in the UC group. These are not realistic assumptions. A brief clinic intervention will not double abstinent rates, especially since 73% of UC patients received some inoffice provider counseling. The 8% abstinent rate in both groups is about what one would expect in patients receiving brief counseling in an outpatient clinic setting.
We agree with the reviewer that the size of the trial groups on which this analysis is based did not provide sufficient statistical power to detect effects sizes of less than RR=2.0. We also agree that this assumption may have been unrealistic concerning complete abstinence, especially considering that this trial recruited unselected tobacco users, i.e. users who were not ready/willing to quit. This is why we also based our analysis also on secondary end-points, such as cutting tobacco use or making a quit attempt, which are much more frequently observed in a time frame of 6 months. Whether these end-points are robust enough to be entered in a cost-effectiveness analysis largely based on avoiding distal health outcomes is discussed in the subsequent answers.
The lack of an intervention effect from a trial is typically considered a fatal flaw for a cost-effectiveness analysis. The authors attempt to rescue this evaluation by broadening the scope into a larger "what if" evaluation. The remaining flaws below are based on an assumption that there is value to conducting the "what if" modeling of a dental clinic smoking cessation intervention. In health economic evaluations, there is much less emphasis on statistically significant differences between groups than in medical research. The reasons are two-folds: the magnitude of cost differences are presumably of interest to decision-makers; and the statistical properties of cost data. These arguments are fully described in the well-known textbook on economic evaluations in medicine by Drummond et al on pages 258-263. In summary, the expected (i.e. the mean) difference in costs is the best measure of effect, and the size of that difference is what matters when making health policy decisions. Decisions based on a non-rejected null-hypothesis (one-sided) based on p-values risk inefficient resource allocation. Cost-effectiveness analysis could be still interesting when the differences in effectiveness are not significant but differences in costs persist. Finally, we would also respectfully argue that any cost-effectiveness analysis based on behavioral outcomes rests on strong and often unverified assumptions ("what if" approach). In the domain of smoking cessation, this is the case with the usually reported outcome "point abstinence"( "7-day abstinence" ) at 6 or 12 months assumed to be a measure of stable lifelong change of smoking behavior.
2) the economic analysis uses only about half of the original population of the original trial (n=205). The underpowered main trial raises an additional question of whether the original study was appropriately powered to detect differences in economic outcomes. Reducing the sample by about half adds to this concern. The authors imply that the sample was reduced because smokers under age 20 were excluded, but the reader is left unsure. Participant cost data are messy in clinical trials, so it would have been good to know if the sample was reduced solely because of the age restriction or if other factors were involved (other than the small percent lost to follow-up).
The sample was reduced to 205 mainly due to the exclusion of smokeless tobacco (snus) users, a decision taken owing to the much less established long-term health consequences of the use of this type of tobacco. This exclusion was clearly reported in the Methods section at page 4, 4th paragraph, see line 33-38 and page 5, line 1-3
3) the authors assumed that the observed differential reduction in amount smoked at 6 months (the only difference between I and UC groups) would lead to substantial quitting additional quitting among the intervention group compared to the UC group. The support for this assumption relies on studies conducted in the 1980s and 1990s, when smoking rates and cigarettes per day were higher that today. The Hyland et al. (2005) study is actually a re-evaluation of an earlier study (Hughes et al., 1999) using longer follow-up of COMMIT study participants (enrolled between 1988 and 1993) . The Hughes analysis found that after 2 and 4 years of follow-up, reducing quantity smoked did not increase quitting. However, Hyland examined follow-up through 2001 and found that those who reduced smoking amount by >50% had a 1.7 higher likelihood of quitting compared to other participants. The implication for this study is that it appears to have taken 10 years to produce an intervention effect associated with reducing the quantity smoked. This would substantially extend the timing of any intervention effect associated with reduced smoking. This does not appear to have been considered. We provided 4 references for our assumption concerning the relation between reducing smoking amount and definite quitting, of which 2 were published in the mid 2000ies. To these, the conclusions of a Cochrane review can be added, showing no difference in quit rates among abrupt quitters and gradual reducers, especially in the most recent studies using pharmacotherapy (Lindson-Hawley N, Aveyard P, Hughes J R. Reduction versus abrupt cessation in smokers who want to quit. Cochrane database of systematic reviews (Online). 2012;11:CD008033) 4) A "do nothing" approach assumed no smokers quit, which is not realistic. Annual population-level quitting in adult populations is between 3-5%. It does not appear that the model allowed for independent quitting, which biases the results toward The reviewer is completely right in pinpointing this misclassification of the outcome in the "do-nothing" alternative. However, we used this scenario as a fictitious comparator for both trial groups (i.e.
"Intervention" and "Usual Care") which is unlikely to have biased the results. In order to make the reader more comfortable with the analysis in the revised version, we omitted the comparisons with the "do nothing" alternative.
5) The analysis suggests that the intervention produced worse quit outcomes than usual care. This is absurd, and is likely the result of random variation among low numbers of study participants in each age group. This is a fundamental flaw associated with the small study sample size. We were not able to identify any single figure in the article supporting the reviewer"s statement that there would be worse quit outcomes in the intervention as compared to the usual care (UC) group, unless the reviewer refers to the (1-person) difference in 7-day abstinence. What the analysis certainly shows is that the cost-effectiveness of the intervention would be lower than UC in one scenario (population impact), for reasons that we present in the 5th paragraph of the discussion, see page 15, line 24-32
The economic analysis (limited to mean intervention cost and cost/quit) should have been added to the primary outcome paper. There is not enough information from the study to support a separate economic evaluation that was presented in this paper. The cost effectiveness of dental clinic smoking cessation is an important issue. However, using this intervention trial as a vehicle is not convincing. We agree that the imprecision of the estimations from this analysis does not convey sufficient information for decision makers as whether there is a convenience in proceeding to large-scale dissemination of this brief intervention. However, this was not the principal scope of this article. Our main aim was rather to illustrate with a real-life example the opposite conclusions one may be forced to reach with the use of different modeling strategies. In order to make this clearer the aims of the study were re-formulated in the abstract and in the manuscript. Whether the conclusions would be radically different with a larger study it remains to be seen.
Reviewer: 2 Mary Lou Chatterton Deakin University, Australia
Typically when an intervention is found not to be effective a cost-effectiveness evaluation isn"t undertaken. The primary trial did not meet its primary endpoint of 7 day abstinence, but did achieve a significant difference in a secondary outcome measure (reduction in tobacco consumption) which would warrant an analysis of the estimated cost-effectiveness. So this evaluation has utility to health care policy makers. However, there are a few areas of the manuscript that would benefit from revision as noted below:
1) The introductory paragraph discusses cigarette smoking while the remaining sections discussion tobacco cessation. Given that the intervention is not exclusive to cigarettes but includes oral tobacco (snus) it may be useful to discuss the burden of all tobacco use if that is available. It may also be helpful to readers to define snus. We agree with the reviewer that mentioning tobacco cessation but concentrating the economic analysis on smoking is confusing. In the revised version we chose not to increase this confusion by adding information on smokeless tobacco, but rather to make it clear throughout the text that the analysis only concerns smoking cessation. We also changed the title of the article and included a rationale for this restriction at page 4 line 34-36
2) I found the reference to Bolin [15] in the introduction confusing. Bolin provides a comprehensive documentation of the models used in economic evaluations of smoking cessation treatments and provides conclusions around improvements to the methods and reporting for these models. It does not recommend a particular type of model for a particular purpose. A Markov model evaluates cohorts which can be representative of a population. Therefore the distinction the authors make between population-based models and Markov models is unclear.
We completely agree with this comment. Of course, a Markov model can be used to evaluate the impact of an intervention on the population level. We have changed this paragraph and used a hopefully clearer terminology to distinguish between the different models used in this study, see page 3, line 26-33
3) There were a few questions regarding the use of the trial results in this economic evaluation: a. Why did the economic analysis only use data from those aged 20 or older?
Thank you for this comment. We added the explanation about the reasons of excluding pf participants younger than 20, years, see page 4, line 36-38 b. Why weren"t the main trial results specifically provided? It would assist the reader if there was a more compelling reason to explain why this economic evaluation with two different models is useful to clinicians and decision makers.
The main trial"s results as well as the calculation of the effectiveness data for the economic evaluation are now provided in Table 1. 4) It may not be appropriate to spread the intervention costs over 5 years (20% each year) as it is currently described. If the actual training occurs in year 1 then these costs should be allocated there. Otherwise the costs being spread out over 5 years may decrease the intervention costs since they would be discounted at 3% in years 2-5.
The intervention was running during 5 months, see page 4, line 18-20 that is why we did not discount the intervention costs at all. Spreading training costs is often used as an approach in health economic evaluations and we provided some references (page 6, line1). But according to your advice, we included the total training costs into the sensitivity analyses (see page 8, line 16) 5) For clarity it would be useful if the authors defined which costs were included in each perspective since both health sector and societal perspectives are presented.
The description of perspectives in to different models are described.
For the population based model page 7. line 21-22: The societal costs include medical treatment costs and municipal costs for care, hence the model adopted a limited societal perspective as patient and productivity costs are not included For the Markov model page 7, line 34-36 : The societal costs include costs associated to: medical treatment, municipal costs for care, drugs, informal care and other expenditures for patients and relatives and loss of productivity 6) The rationale for the choice of 2014 as the reference year for costs should be noted.
The rationale for choice of 2014 is now added into the Method-section, Health Economic Evaluationparagraph, see page 5, line 17-21. Originally, the four risk factor were included into the RHS-model: obesity, smoking, lack of physical activity and risky consumption of alcohol. While adapting the model for the current study, only the disease related to smoking were included, see page 6, line 30 -33.
8) Additional detail regarding the main study endpoints and how they are adapted for use in the models would be helpful to the reader.
Additional information about the study endpoint used in this analyses is added, see page 6, line 24-25 9) In the current manuscript a description of how the QALYs are calculated should be added.
Additional information about QALYs calculation in different model is added:
For the population model, page 7, line 16-18
For the Markov model, page 8 line 1-4
10) It would help the reader if there was additional information in table 3 such as the fact the data provided was compared to the do nothing alternative. At the moment it is not clear without reading the text. It would be useful if the results for both models were stated using economic evaluation terminology such as "incremental cost effectiveness" and "dominant" interventions. The brief novel counselling was dominated by the usual care option (meaning it was the least costly alternative and was also estimated to deliver more QALYs).
Thank you for this valuable comment. We omitted the comparisons with the "do nothing" alternative. The table 3 was revised and now includes the necessary information 11) I don"t entirely agree with the discussion that, " The opposite conclusions from the two models are probably best explained by the difference in the population to which the simulation is applied." The fact that the Markov model included medications and lost productivity costs as well as covered a lifetime horizon are additional reasons for differences in the results.
We agree with your comment and this was mentioned in the discussion, see page 15, line 17-23 VERSION 2 -REVIEW REVIEWER Mary Lou Chatterton Deakin University, Australia REVIEW RETURNED 01-May-2017
GENERAL COMMENTS
The previous comments have been addressed adequately.
